Lv1
20 积分 2022-08-30 加入
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
19小时前
已完结
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
1个月前
已完结
Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy
1个月前
已完结
Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy
1个月前
已关闭
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
2个月前
已完结
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
2个月前
已完结
门静脉癌栓分型与治疗选择
2个月前
已完结
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
4个月前
已完结
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors
4个月前
已完结
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
4个月前
已完结
皖公网安备34019202002308
